Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure). Ligand financing agreement with AvenCell Therapeutics, a clinical-stage developer of controllable allogeneic CAR-T therapies.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Ligand financing agreement with AvenCell Therapeutics, a clinical-stage developer of controllable allogeneic CAR-T therapies
- Transaction provides AvenCell up to $47 million in financing
- Exposure to cancer cell-therapy platform, with potential strategic upside and clinical-development risk
- Exhibit 99.1 contains transaction terms and other material details for investor review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.